Hubert Rehrauer

Country flagSwitzerland

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Amniotic fluid has been proposed as an easily available source of cells for numerous applications in regenerative medicine and tissue engineering. The use of amniotic fluid cells in biomedical applications necessitates their unequivocal characterization; however, the exact cellular composition of amniotic fluid and the precise tissue origins of these cells remain largely unclear. Using cells cultured from the human amniotic fluid of fetuses with spina bifida aperta and of a healthy fetus, we performed single-cell RNA sequencing to characterize the tissue origin and marker expression of cultured amniotic fluid cells at the single-cell level. Our analysis revealed nine different cell types of stromal, epithelial and immune cell phenotypes, and from various fetal tissue origins, demonstrating the heterogeneity of the cultured amniotic fluid cell population at a single-cell resolution. It also identified cell types of neural origin in amniotic fluid from fetuses with spina bifida aperta. Our data provide a comprehensive list of markers for the characterization of the various progenitor and terminally differentiated cell types in cultured amniotic fluid. This study highlights the relevance of single-cell analysis approaches for the characterization of amniotic fluid cells in order to harness their full potential in biomedical research and clinical applications.

Year:

2023

Pleural mesothelioma (PM) is a cancer where epithelioid, biphasic and sarcomatoid histotypes are observed. Sarcomatoid PM is characterized by mesenchymal features. Multi-omics have been used to characterize the epithelial-to-mesenchymal (EMT) phenotype at the molecular level. We contribute to this effort by including the analysis of RNA editing. We extracted samples with the highest vs. lowest Epithelial score from two PM cohorts and observed increased RNA editing in introns and decreased RNA editing in 3′UTR upon EMT. The same was observed in primary PM primary cultures stratified by transcriptomics analysis into two groups, one of them enriched with mesenchymal features. Our data demonstrate that, as has been observed in other cancer types, RNA editing associates to EMT phenotype in PM.

Year:

2023

Year:

2022

Collaborators (22)

Miguel Tavares Pereira

Lecturer

Utrecht University

NETHERLANDS
View details

Marta Roccio

-

SWITZERLAND
View details

Yasutaka Mitamura

-

SWITZERLAND
View details

Thomas Biedermann

-

SWITZERLAND
View details

Isabelle C. Arnold

Assistant Professor

University of Zurich

SWITZERLAND
View details

Ari Molofsky

Associate Professor

University of California, San Francisco

UNITED STATES
View details

Manfred Kopf

Professor

ETH Zürich

SWITZERLAND
View details

Christoph Schneider

University of Zurich

SWITZERLAND
View details

David Legouis

University of Geneva

SWITZERLAND
View details

Ivan Ivanovski

University of Zurich

SWITZERLAND
View details

Melanie Greter

University of Zurich

SWITZERLAND
View details

Reza Asadollahi

Senior Lecturer in Genetics

University of Greenwich

UNITED KINGDOM
View details

Basak Corak

University of Zurich

SWITZERLAND
View details

Ueli Moehrlen

-

SWITZERLAND
View details

Albert Edge

Professor

Massachusetts Eye and Ear

UNITED STATES
View details

Sinduya Krishnarajah

University of Zurich

SWITZERLAND
View details

Thimios Mitsiadis

Professor

Universität Zurich Medizinische Fakultät

SWITZERLAND
View details

Emanuela Felley‐Bosco

-

SWITZERLAND
View details

Andrew M. Hall

University of Zurich

SWITZERLAND
View details

Anita Rauch

-

SWITZERLAND
View details

Burkhard Becher

University of Zurich

SWITZERLAND
View details

Stellor Nlandu Khodo

Senior scientist/Head of Ambizione group

University of Zurich

SWITZERLAND
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.